UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/531,547	11/16/2005	Chaitan Khosla	STAN-258US5	3888
	7590 04/02/200 d & Francis LLP	EXAMINER		
Stanford University Office of Technology Licensing			CHEU, CHANGHWA J	
1900 University Avenue Suite 200		ART UNIT	PAPER NUMBER	
East Palo Alto, CA 94303			1641	
			MAIL DATE	DELIVERY MODE
			04/02/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/531,547	KHOSLA ET AL.
Office Action Summary	Examiner	Art Unit
	JACOB CHEU	1641
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet with t	he correspondence address
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory perion.  - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the main earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply will apply and will expire SIX (6) MONTHS ute, cause the application to become ABANE	FION.  be timely filed  from the mailing date of this communication.  DONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 3/1 2a) This action is <b>FINAL</b> . 2b) The 3) Since this application is in condition for allow closed in accordance with the practice under	nis action is non-final. vance except for formal matters	
Disposition of Claims		
4) ☐ Claim(s) 1-28 is/are pending in the application 4a) Of the above claim(s) is/are withdrest is/are allowed.  5) ☐ Claim(s) is/are allowed.  6) ☐ Claim(s) is/are rejected.  7) ☐ Claim(s) is/are objected to.  8) ☐ Claim(s) 1-28 are subject to restriction and/or and/or allowed.	rawn from consideration.	
Application Papers		
9) The specification is objected to by the Examination The drawing(s) filed on is/are: a) and a specificant may not request that any objection to the Replacement drawing sheet(s) including the correct of the specific to by the latest and the specific to be specification.	ccepted or b) objected to by the drawing(s) be held in abeyance. ection is required if the drawing(s) i	See 37 CFR 1.85(a). s objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of:      1. ☐ Certified copies of the priority docume 2. ☐ Certified copies of the priority docume 3. ☐ Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a list	nts have been received. nts have been received in Appl iority documents have been rec eau (PCT Rule 17.2(a)).	ication No beived in this National Stage
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/M	mary (PTO-413) ail Date nal Patent Application

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-8, 10-11, 21-28, drawn to using a purified gluten oligopeptide for diagnosing Celiac Sprue in an individual, with special technical feature of the oligopeptide and detecting the presence of antibodies that specifically bind to the oligopeptide.

Group II, claim(s) 1-7 and 9, drawn to drawn to using a purified gluten oligopeptide for diagnosing Celiac Sprue in an individual, with special technical feature of determining whether an oligopeptide would stimulate agglutination of anti-gliadin antibodies, anti-tTGase antibodies or combination thereof from the individual.

Group III, claim(s) 12-17, 19-20, drawn to drawn to using a purified gluten oligopeptide for diagnosing Celiac Sprue in an individual, with special technical feature of the oligopeptide as recited in SEQ ID No.12.

Group IV, claim(s) 12-16 and 18, drawn to with special technical feature of determining whether an oligopeptide of SEQ ID No. 12 would stimulate agglutination of anti-gliadin antibodies, anti-tTGase antibodies or combination thereof from the individual.

According to 37 CFR 1.475 regarding unity of invention:

(a) An international and a national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ("requirement of unity of invention"). Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a

contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

(b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:

- (1) A product and a process specially adapted for the manufacture of said product; or
- (2) A product and a process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specifically designed for carrying out the said process; or
- (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.

If an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b) above, unity of invention might not be present. Furthermore, the determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim.

The above invention in Groups I-IV, each falls into the category of (b)(2) of 37 CFR 1.475, namely product and a process of use said product. Applicant is entitled to elect one group for examination under 37 CFR 1.475.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not

Application/Control Number: 10/531,547 Page 4

Art Unit: 1641

distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

2. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JACOB CHEU whose telephone number is (571)272-0814. The examiner can normally be reached on 9:00-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Jacob Cheu/ Examiner, Art Unit 1641